Medtronic (MDT) Stock Forecast & Price Target

Medtronic is poised for a positive outlook as it benefits from a stable global CRM market and demonstrates improving organic growth, particularly driven by its Cardiovascular and Diabetes segments, which grew from 5.5% to 6.0% in F3Q26. The company's innovative products, such as the Affera Sphere-9 and Symplicity Spyral RDN, are expected to contribute significantly to revenue growth, showing the potential for a robust product cycle. Furthermore, management's efforts to expand sales channels, along with possible positive margin improvements and favorable currency impacts, reinforce the optimistic projections for Medtronic's financial performance.

The analysis identifies significant challenges facing Medtronic's stock, as evidenced by declining market share in critical segments such as the spine and neuromodulation markets, where market share decreased by 20 and 30 basis points year-over-year, respectively. Additionally, the company's revenue growth is projected to slow to less than 5% due to unsuccessful new product launches and increasing competition, which could hinder its ability to regain lost market share. Furthermore, declining gross and operating margins, reflected by a 170 basis point drop in non-GAAP gross margin and a 210 basis point decrease in non-GAAP operating margin year-over-year, suggest a negative trend in profitability that could lead to below-consensus earnings and further financial instability.